United States Bile Duct Cancer Market Insight
Published: 13 June 2026 | Report Format: Electronic (PDF)
The United States Bile Duct Cancer Market is projected to grow at a CAGR of 9.7%, driven by rising cholangiocarcinoma incidence, increasing adoption of targeted therapies, expanding immunotherapy use, and advances in precision oncology diagnostics.
United States Bile Duct Cancer Market Forecasts to 2035
- The United States Bile Duct Cancer Market Size was Estimated at USD 0.63 Billion in 2025.
- The Market Size is Expected to Grow at a CAGR of around 9.7% from 2025 to 2035.
- The United States Bile Duct Cancer Market Size is Expected to Reach around USD 1.59 Billion by 2035.
Notable Insights in the United States Bile Duct Cancer Market
- Segmentation Based on Therapy Type, the Targeted Therapy segment held a dominant position in the United States Bile Duct Cancer Market in 2025 with nearly 41.8% share, supported by growing biomarker testing and FGFR2-directed treatment adoption.
- Segmentation Based on Cancer Type, the Intrahepatic Cholangiocarcinoma segment accounted for approximately 62.4% share in 2025, driven by its higher diagnosed prevalence and increasing availability of molecularly guided therapies.
- The United States Bile Duct Cancer Market is led by AstraZeneca PLC, Incyte Corporation, and Eli Lilly and Company, with combined revenues of approximately USD 104.99 billion in 2025, reflecting strong oncology portfolios and sustained R&D investments.
- Growing investments in precision oncology continue to intensify competition, while AstraZeneca reported USD 54.07 billion, Eli Lilly generated USD 45.04 billion, and Incyte recorded USD 5.88 billion in 2025 revenues, supporting pipeline expansion.
Download the eBook (ToC)
What Makes Decisions Advisors Research Unique?
- Intelligent Market Research Based on AI for Semiconductors & Optoelectronics
Decisions Advisors offers intelligent market research which includes advanced analysis of infrared sensor technologies, optoelectronic semiconductors, AI-driven sensing solutions, and remote sensing. Our research identifies potential areas of business development, technology adoption rates, competitive position analysis, and important strategic changes in South Korea Remote Sensing Infrared Light Emitting Diode Market.
- Highly Effective Research Approaches with Accurate Forecast Analysis
The research process uses advanced methodologies such as primary research interview approaches, industry research, tracking the semiconductor value chain, and data triangulation to deliver accurate market sizing, CAGR forecasting, investment analysis, and technology forecasting. The study examines the demand for semiconductor solutions in automotive electronics, industrial automation, health care monitoring, and smart surveillance applications in South Korea.
- Highly Competitive Environment Analysis
In-depth analysis of key infrared LED players, optoelectronic semiconductor innovations, AI-enabled sensing solutions, product launch activities, and collaborations is included in the report. The report also covers semiconductor regulations, technology research and development analysis, smart sensor infrastructure, and new opportunities available in the South Korea Remote Sensing Infrared Light Emitting Diode Market.
Competitive Analysis:
The report offers the appropriate analysis of the key organizations/companies involved within the United States bile duct cancer market, along with a comparative evaluation primarily based on their product of offering, business overviews, geographic presence, enterprise strategies, segment market share, and SWOT analysis. The report also provides an elaborative analysis focusing on the current news and developments of the companies, which includes product development, innovations, joint ventures, partnerships, mergers & acquisitions, strategic alliances, and others. This allows for the evaluation of the overall competition within the market.
Top Companies in the United States Bile Duct Cancer Market
-
-
- AstraZeneca PLC
- Incyte Corporation
- Eli Lilly and Company
- Merck & Co., Inc.
- Roche Holding AG
- Pfizer Inc.
- Jazz Pharmaceuticals plc
- Taiho Pharmaceutical Co., Ltd.
- Servier Pharmaceuticals LLC
- Exelixis, Inc.
-
Recent Developments:
- In April 2025, AstraZeneca PLC launched expanded clinical development initiatives for IMFINZI in biliary tract cancers, strengthening its immunotherapy portfolio and advancing combination treatment approache.
- In June 2025, Eli Lilly and Company collaborated with Incyte Corporation to explore precision oncology opportunities and accelerate development strategies targeting rare gastrointestinal malignancies.
Market Segmentation:
United States Bile Duct Cancer Market, By Therapy Type
- Chemotherapy
- Targeted Therapy
- Immunotherapy
- Radiation Therapy
- Surgery
United States Bile Duct Cancer Market, By Cancer Type
- Intrahepatic Cholangiocarcinoma
- Extrahepatic Cholangiocarcinoma
United States Bile Duct Cancer Market, By Route of Administration
- Oral
- Injectable
United States Bile Duct Cancer Market, By Distribution Channel
- Hospital Pharmacies
- Retail Pharmacies
- Specialty Pharmacies
- Online Pharmacies
United States Bile Duct Cancer Market, By End User
- Hospitals
- Specialty Cancer Centers
- Ambulatory Surgical Centers
- Research Institutes
Expert Views:
The United States Bile Duct Cancer Market is anticipated to witness substantial growth through 2035, supported by expanding precision medicine initiatives, increasing molecular diagnostics adoption, and accelerating targeted therapy innovation. Product launches and strategic collaborations among leading companies are expected to intensify competition and improve treatment outcomes across the oncology landscape.
Author: Komal and Radhika By Decisions Advisors and Consulting